A detailed history of Macquarie Group LTD transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 58,000 shares of RCKT stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,000
Previous 58,000 -0.0%
Holding current value
$1.07 Million
Previous $1.56 Million 20.1%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 21, 2023

SELL
$15.5 - $22.76 $4,913 - $7,214
-317 Reduced 0.54%
58,000 $1.14 Million
Q3 2022

Nov 14, 2022

SELL
$12.37 - $18.41 $7,186 - $10,696
-581 Reduced 0.99%
58,317 $940,000
Q1 2021

May 14, 2021

SELL
$43.34 - $65.91 $11,961 - $18,191
-276 Reduced 0.47%
58,898 $2.61 Million
Q2 2020

Aug 11, 2020

BUY
$13.32 - $22.61 $15,637 - $26,544
1,174 Added 2.02%
59,174 $1.24 Million
Q2 2019

Aug 14, 2019

BUY
$15.0 - $19.81 $45,000 - $59,429
3,000 Added 5.45%
58,000 $870,000
Q1 2019

May 15, 2019

BUY
$13.45 - $19.01 $470,750 - $665,350
35,000 Added 175.0%
55,000 $965,000
Q4 2018

Feb 15, 2019

BUY
$11.21 - $23.53 $224,200 - $470,600
20,000 New
20,000 $296,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.4B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.